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OBJECTIVES: Vocal tremors, which cause social difficulties for patients, may be classified as resting or action
tremors. Of the vocal action tremors, essential and dystonic tremors are the most common. Botulinum toxin and
oral medications have been used to treat vocal tremors, but no comparative clinical trials have been performed.
The aim of this study was to compare the effects of botulinum toxin injection and the oral administration of
propranolol in the treatment of essential and dystonic vocal tremors.
METHODS: This clinical trial recruited 15 patients, divided into essential and dystonic vocal tremor groups.
Patients in both groups received successive treatment with botulinum toxin and propranolol. The treatments
were administered at different times; the order of treatment was randomly selected. Patients were assessed
with flexible nasofibrolaryngoscopy and with perceptual and acoustic voice evaluations. A statistical signifi-
cance level of 0.05 (5%) was used.
RESULTS: Botulinum toxin produced statistically significant improvements in perceptual measures of vocal
instability in patients with dystonic vocal tremors compared with baseline values and treatment with pro-
pranolol. The acoustic measure of variability in the fundamental frequency was significantly lower in patients
with dystonic vocal tremors after treatment with botulinum toxin.
CONCLUSION: Essential and dystonic vocal tremors responded differently to treatment. Dystonic vocal tremors
responded significantly to treatment with botulinum toxin but not oral propranolol. Essential vocal tremors did
not respond significantly to either treatment, perhaps due to the small number of patients, which is a limitation
of this research.
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’ INTRODUCTION
Vocal tremor is a phonatory, rhythmic voice change char-
acterized by involuntary oscillating movements (1) that can
alter vocal production and affect communication, social inter-
action, and quality of life to a greater or lesser degree depend-
ing on the individual.
Essential tremor is the most common type of vocal tremor,
followed by Parkinson’s disease and dystonic tremors (2).
Essential and dystonic tremors are both action induced but
are clinically different (3). Essential vocal tremor is observed
in all postures produced by the larynx, both phonatory and
non-phonatory (4). Dystonic vocal tremor is phonation dependent
and does not occur in non-phonated emissions. These postures
and specific tasks should be evaluated by nasofibrolaryngoscopy
to classify and differentiate the types of vocal tremors (5,6).
Injection of botulinum toxin into the thyroarytenoid (TA)
muscle is the primary treatment choice for dystonia (7).
However, a comparable level of treatment success is not
observed with essential tremors (3), perhaps because several
muscles are involved in this disorder, as has been observed in
electromyographic studies (8). The orally administered beta-
blocker propranolol is generally poorly effective in treat-
ing essential vocal tremors, although it usually decreases
or eliminates tremors in the extremities (9-11). Some studies
have reported an improvement in essential tremors using
botulinum toxin, coinciding with a reduction in laryngeal
tremors and supraglottic hyperfunction, as identified with
perceptual, acoustic, and aerodynamic analyses (9-12). How-
ever, Warrick et al. (13) published a prospective study in
which most patients showed no improvements in objective
acoustic measures when given botulinum toxin.
No published studies have compared the responses of the
two most frequently occurring types of action-induced vocalDOI: 10.6061/clinics/2018/e87
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tremors to treatment with botulinum toxin injection and
oral medications. Information regarding the responses to the
two therapeutic approaches, along with objectively established
clinical diagnoses, will aid in the treatment of patients with
vocal tremors. The objective of this study was to verify and
compare the responses of patients with essential and dystonic
vocal tremors to treatment with botulinum toxin injected into
the TA muscle and oral administration of propranolol.
’ METHODS
The study was approved by the ethics and research com-
mittee (CEP no. 87040/12) and was registered at the Institute
of Scientific and Technological Information in Health, identi-
fied by the Brazilian Registry of Clinical Trials with the code
389mzn. (http://www.ensaiosclinicos.gov.br/rg/rbr-389mzn).
Individuals treated for vocal tremor in the neurolaryngology
clinic of a university hospital between January 2012 and August
2013 were included in this randomized clinical trial. All patients
read, understood, and signed an informed consent form.
Patients included were over 18 years of age and had been
diagnosed with either dystonic or essential vocal tremor.
Exclusion criteria were contraindications for the use of beta-
adrenergic blockers, laryngeal paralysis or morphological
lesions in the phonation apparatus, and signs of Parkinson’s
or cerebellar disease.
Twenty-three individuals with vocal tremors were selected
for the study. Of these 23 patients, 6 were excluded due
to cardiopulmonary contraindications, 1 due to death, and
1 due to adverse effects of propranolol. Of the remaining
15 patients, 10 had dystonic tremor and 5 had essential
tremor (Figure 1) (14). Of the 5 patients with essential tremor,
4 presented tremors of the hands, and 4 had a family history
of tremors. No patient reported improvements in tremors
with alcohol intake, although 3 of them did not use alcohol.
The 10 patients with dystonic tremors presented tremors in
the palate and larynx only.
All patients underwent nasofibrolaryngoscopy, which was
performed without topical nasal anesthesia. Each patient
was asked to perform the following tasks: the prolonged
emission of phonemes (/E/ usual tone, /s/, and /z/), quiet
breathing, and a continuous whistle. The tasks were per-
formed for at least 5 seconds. The examinations were perfor-
med under continuous halogen lighting with a flexible endoscope
(FNL-15RP3, Pentax, Tokyo, Japan) connected to a video
camera (IK-CU44A, Toshiba, Tokyo, Japan) and were
digitally recorded.
The nasofibrolaryngoscopy video images were edited to
identify each task performed and to exclude sounds. After
editing, the videos were coded and recorded on DVD. The
examinations were distributed randomly for recording.
Three otolaryngologists with experience in neurolaryngology,
who were blinded to the patients’ identities, performed a
perceptual-visual analysis of the videos. Diagnoses were made
by observing tremors that occurred during vowel production
and during the tasks that separated the two types of action
tremors, i.e., emission of the continuous /s/ and the whistle.
Tremors were classified as essential when observed during the
execution of both types of tasks and dystonic when not
observed during the emission of /s/ and the whistle (5,6).
Therapeutic interventions
The patients received 2 treatments: percutaneous injection
of botulinum toxin type A into the left TA muscle under
electromyographic guidance, and oral administration of a
beta-adrenergic blocker (propranolol). The order in which the
two treatments were performed was determined randomly;
the date for each type of treatment was selected, and patients
Figure 1 - Flow diagram of the phases in the parallel randomized trial of the two groups of vocal tremor patients.
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who randomly arrived on that date received the treatment.
Botulinum toxin (Dysport - APSEN) was administered at a
dose of 15 units, reconstituted to a concentration of 1 unit in
0.1 ml of normal saline. The propranolol total daily dose was
80 mg, administered in the morning and afternoon. The same
dose was maintained from the beginning until the end of
treatment.
Before the treatments began, the patients’ voices were
recorded. Three weeks after each treatment was initiated,
patients underwent a second nasofibrolaryngoscopy proce-
dure to confirm the efficacy of the treatment and provide a
second voice recording for subsequent perceptual assess-
ments and acoustic analyses. Patients who received botuli-
num toxin in the first round of treatment (n=7) waited
6 months before beginning a second round of treatment with
oral propranolol. Patients who received oral propranolol in
the first round (n=9) had a 2-month washout period without
treatment before beginning the second round of treatment
with botulinum toxin. One of the patients died from an
unknown cause before completing the treatment (Figure 1).
Perceptual and acoustic analyses
Vocal tasks performed by each participant included the
sustained emission of the vowel /E/ at a comfortable and
auto-regulated intensity and frequency, recorded before and
3 weeks after the start of each treatment. Patients recorded
their voices while seated in a silent environment using a
unidirectional headset microphone with a flat response curve
positioned 1 cm diagonally from the corner of the mouth
and coupled to a desktop computer. Voices were recorded
directly into audio editing software (Sound Forge version 4.5,
Sony) with the audio input set using the volume control
function of the software. Each voice sample was edited in
the audio editing software, excluding the start of each emis-
sion but retaining approximately the subsequent 3 seconds.
A total of 45 voice samples were analyzed, 3 from each of the
15 included patients, before and after each treatment; 20% of
the repetitions (9 voices) were also analyzed to verify intra-
rater reliability. The vocal emissions underwent two types of
analysis, perceptual and acoustic, which were based on the
overall degree of vocal deviations and the instability of the
sustained long vowel /E/ on a visual analog scale of 100
points, where 0 indicated no change and 100 indicated the
maximum change. The evaluations were made indepen-
dently; the assessments made by the reviewer with the
greater reliability (91.26%) were used in this study (Table 1).
The acoustic analysis of the voices was performed with
VoxMetria version 2.7h (CTS Informática).
The extracted acoustic parameters of the phonations
included jitter, shimmer, and variability of the fundamental
frequency in semitones.
Statistical analysis
The Mann-Whitney test was used to compare pretreatment
quantitative variables, including the overall degree of voice
change, vocal instability, jitter, shimmer, and variability of
the fundamental frequency, between the vocal tremor groups,
essential and dystonic. The Wilcoxon test was used to com-
pare the responses to the two treatments based on the
perceptual evaluation results obtained before and after
treatment for each vocal tremor group. The significance level
adopted for this study was 0.05 (5%). Statistical analyses were
performed using SPSS v.17 (IBM, Armonk, NY), Minitab 16
(Minitab, State College, PA), and Excel (Office 2010, Microsoft,
Redmond, WA).
’ RESULTS
Table 1 shows the comparisons of the perceptual evalua-
tion parameters (overall degree of vocal change and vocal
instability) and also presents a pretreatment comparison of
the parameters of the acoustic assessment (jitter, shimmer,
and variability of the fundamental frequency) between patients
with dystonic and essential tremors. Statistical analyses revealed
no significant differences between the two types of tremors for
the parameters assessed.
Table 2 presents the perceptual and acoustic assessment
results for patients with essential tremors after treatment,
compares the results of each treatment with the pretreatment
values, and compares the results of the two treatments. There
were no statistically significant differences.
Table 3 presents the perceptual and acoustic assessment
results for patients with dystonic tremors after treatment,
compares the results of each treatment with the pretreatment
values, and compares the results of the two treatments. Sta-
tistical analysis showed that the overall level of change, vocal
instability, and variability of the fundamental frequency were
significantly lower after the administration of botulinum
toxin than before the treatment. The use of propranolol led to
no statistically significant differences. The differences between
botulinum toxin and propranolol in the overall level of vocal
change, jitter, and shimmer were nonsignificant. The variability
of the fundamental frequency and vocal instability values were
significantly lower after the injection of botulinum toxin than
after the administration of oral propranolol.
’ DISCUSSION
This randomized study compared the responses of the most
common types of action-induced vocal tremors, essential and
Table 1 - Pretreatment comparison of perceptual and acoustic
parameters between patients with dystonic and essential tremors.





















N, number of participants; SD, standard deviation; F0, fundamental frequency.
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dystonic, to the injection of botulinum toxin into the TA and the
oral administration of propranolol.
The classification of essential and dystonic vocal tremors,
which are physiologically distinct, was made through eval-
uations with nasofibrolaryngoscopy during unvoiced tasks.
The two types of tremor did not differ in the perceptual
evaluation of voiced sounds or in acoustic analysis, based on
the parameters evaluated in the pretreatment period (Table 1).
For patients with essential tremor, the comparison of the
two treatment methods by perceptual and acoustic analyses
revealed no statistically significant differences (Table 2). Simi-
larly, no statistically significant differences were observed
before and after treatment. The results for the vocal insta-
bility and variability of the fundamental frequency values
suggested a better response to propranolol than to botulinum
toxin (Table 2). A study using a larger sample of patients
could potentially confirm this trend. Warrick et al. (9) reported
that vocal parameters in a patient with essential vocal tremor
improved after 16 weeks of bilateral administration of 2.5 units
of botulinum toxin into the TA muscles. In the same year,
however, the authors published a prospective study comparing
unilateral and bilateral botulinum toxin injections in patients
with essential tremor. In that study, only 3 of the 10 patients
who received bilateral injections and 2 of 9 patients who
received unilateral injections experienced improvements in the
acoustic measurements of tremor. The authors also reported
that 8 of the 10 patients requested a reinjection of the botulinum
toxin because of vocal effort; however, the authors emphasized
the need for further studies to clarify the subgroups likely
to benefit from this treatment. Adler et al. (12) evaluated 13
patients with essential vocal tremor who received 1.25 units,
2.5 units, or 3.75 units of botulinum toxin in each vocal cord.
The authors found a progressive improvement with increas-
ing dose, based on perceptual and acoustic parameters and
videolaryngostroboscopy. Kendall and Leonard (15) presented
a series of 4 patients with vocal tremors who received
botulinum toxin injections in the TA and interarytenoidal
muscles; the results of injections into only the TA muscle were
not beneficial, as observed by laryngeal dystonia. The authors
concluded that the combination of injections into the two
Table 2 - Perceptual and acoustic assessment results for patients with essential tremors before and after the administration of
botulinum toxin and propranolol, comparing the results of each treatment method with pretreatment values and comparing the
results of the two treatments.
N Mean Standard deviation P1 value P2 value
Overall Level of change Pre 5 92.0 8.4 - x -
BT 5 82.6 18.0 0.336 0.345
PP 5 71.6 33.1 0.109
Vocal instability Pre 5 90.0 12.2 - x -
BT 5 73.0 22.8 0.104 1.000
PP 5 70.8 29.9 0.068
Jitter Pre 5 4.76 4.69 - x -
BT 5 3.90 3.82 0.686 0.893
PP 5 4.10 5.72 0.500
Shimmer Pre 5 24.56 14.69 - x -
BT 5 20.41 10.24 0.500 0.893
PP 5 21.21 19.18 0.686
Variability of F0 Pre 5 11.60 4.98 - x -
BT 5 8.20 3.42 0.225 0.893
PP 5 9.00 7.07 0.077
Pre, pretreatment; BT, botulinum toxin; PP, propranolol; F0, fundamental frequency; N, number of participants; P1, comparison of each treatment method
before and after treatment; P2, comparison between treatments.
Table 3 - Perceptual and acoustic assessment results for patients with dystonic tremors before and after the administration of
botulinum toxin and propranolol, comparing the results of each treatment method with pretreatment values and comparing the
results of the two treatments.
N Mean Standard deviation P1 value P2 value
Overall level of change Pre 10 78.0 15.5 - x -
BT 10 60.5 16.9 0.031* 0.059
PP 10 77.5 19.3 0.953
Vocal instability Pre 10 79.5 13.8 - x -
BT 10 50.0 18.3 0.007* 0.024*
PP 10 78.3 20.5 0.959
Jitter Pre 10 3.17 4.65 - x -
BT 10 2.94 4.76 0.386 0.508
PP 10 4.17 5.45 0.959
Shimmer Pre 10 21.26 14.08 - x -
BT 10 17.45 13.13 0.386 0.386
PP 10 22.64 17.70 0.799
Variability of F0 Pre 10 11.00 4.78 - x -
BT 10 5.40 3.34 0.011* 0.050*
PP 10 10.70 6.09 0.683
Pre, pretreatment; BT, botulinum toxin; PP, propranolol; F0, fundamental frequency; N, number of participants; P1, comparison of each treatment method
before and after treatment; P2, comparison between treatments; * po0.050.
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muscles could improve the voice quality of low-risk patients.
This method could provide an alternative treatment for patients
but may have the potential for aspiration. Gurey et al. (16), in a
retrospective analysis of 16 patients with essential tremors who
had received botulinum toxin in both vocal muscles, observed a
symptomatic improvement and reduction in tremor amplitude
in the larynx in all patients. Of these patients, 50% had not
responded well to therapy with oral medications. The authors
concluded that botulinum toxin was useful in patients with
essential tremors and that the doses and application sites
should be individualized according to tremor characteristics,
symptoms, and adverse effects. Lorenz and Deuschl (17)
discussed the traditional view that essential tremor has no
well-defined cause and mechanism because it is not an isolated
condition. They stated that the heterogeneity of the disease
is caused by gaps in diagnostic criteria and the diversity of
neurological manifestations that may be associated with
tremors. Controlled studies with larger numbers of patients
may help define the best treatment. However, the possibility of
satisfactory responses to either treatment justifies the use of
both in clinical practice. Patients selected for the current study
spontaneously sought out medical help with a complaint of
vocal tremor, which is not common in cases of essential tremors
in general. Although vocal tremor is not uncommon in these
patients, it is usually less important to the patient. In addition,
the majority of patients excluded during the survey were from
the essential tremor group. Thus, the patients in the essential
tremor group shown in Table 2 showed better absolute values
in terms of the overall levels of change, vocal instability and
variability of F0. Maybe due to the small number of patients,
we did not have statistically significant results in the essen-
tial vocal tremor group, which is a limitation of this research.
However, compared with the absolute values in Table 3,
where there was a statistically significant difference, lower
values were observed in the essential tremor group (Table 2).
Studies with a higher number of patients are desirable.
In patients with dystonic tremors, the assessment of the
overall level of vocal changes showed a tendency towards a
statistically significant difference, with minor changes after
the use of botulinum toxin compared to propranolol (Table 3).
A study with a larger number of patients might result in a
significant difference. Vocal instability was significantly lower
after the administration of botulinum toxin than after the
administration of propranolol (Table 3). The difference in the
variability of the fundamental frequency between the two
treatments in patients with dystonic tremors was statistically
significant; botulinum toxin injection produced better results
(Table 3). This parameter is highly associated with tremor
because it measures variations in the fundamental frequency,
and its decrease is related to improvements in tremor. Com-
parisons of assessments of perceptual parameters before and
after the treatments showed a statistically significant difference
for the parameter of vocal instability, with a better response to
botulinum toxin injection in patients with dystonic tremors.
The comparison of acoustic data before and after the treatments
also showed a statistically significant difference in the vari-
ability of the fundamental frequency with the use of botulinum
toxin injections in patients with dystonic tremors (Table 3). The
average variability of the fundamental frequency was very
close to normal values. The variability of the fundamental
frequency is an objective acoustic parameter that demonstrated
differences between treatments and indicated a good response
to botulinum toxin injection in patients with dystonic tremors;
it must be taken into account in the evaluation and monitoring
of patients with vocal tremors. Maronian et al. (3) reported
improvements and patient satisfaction in a study of 44 patients
with dystonic tremors who received botulinum toxin injections
in the lateral cricoarytenoid (21 patients, 48%) or TA muscles
(23 patients, 52%); the two groups exhibited similar treatment
responses. Injection into the lateral cricoarytenoid muscle could
be an option for patients with dystonic tremors, but it may
have adverse effects, such as dysphagia, vocal breathiness,
and hoarseness. Fasano et al. (18), in a systematic review
of 43 publications and 487 patients, reported difficulty in
evaluating the effectiveness of treatments for different types
of vocal tremors. The interventions were numerous, with oral
medications, injectable medications, and stimulants used for
different types of tremors, with highly variable results that
depended on dosage, application site, and tremor distribution.
Most studies investigated the application of botulinum toxin,
generally finding improvements in tremors mainly of the
head and vocal cords. The authors concluded that randomized
controlled trials were needed.
The present study, although randomized, was not double-
blinded for ethical reasons because of the impossibility of
placebo injections into the muscle. However, the subjective
perceptual evaluations and objective acoustic evaluations
were blinded. The evaluator did not know the patients and
was also unaware of the time period and treatment corres-
ponding to each voice recording. The comparison of the two
types of tremors showed that they do not differ in perceptual
or acoustic evaluations but did respond differently to treat-
ment with botulinum toxin and propranolol. The response of
dystonic tremors to botulinum toxin injections was statisti-
cally significant in perceptual and acoustic assessments; this
was not observed with essential tremors. Hence, it is impor-
tant to establish the correct vocal tremor diagnosis in order to
offer the proper treatment to the patient and to determine an
informed prognosis. The specific measures of vocal instabil-
ity used here were more sensitive than other parameters for
detecting differences, even in a small group of patients; thus,
we recommend that these measures be prioritized among the
general perceptual and acoustic measures.
Dystonic and essential vocal tremors are unusual, although
they are the most common types of vocal tremors. The fact
that they affect elderly patients complicates the use of beta-
adrenergic blocking drugs. In this study, 7 patients were
excluded because of the impossibility of using this treatment
(Figure 1). Further studies with a larger number of patients
comparing different doses of botulinum toxin, bilateral and
unilateral administration, injections in other intrinsic muscles,
and the administration of other oral drugs may supply new data
to support clinical applications in patients with vocal tremors.
’ CONCLUSIONS
1. Dystonic and essential tremors differ in their responses to
treatments.
2. Dystonic tremor responds significantly to the injection of
botulinum toxin but not to the use of oral propranolol.
3. Essential tremor does not respond significantly to either
treatment.
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